Cargando…

82. Assessment of Clinical Outcomes and Antibiotic Prescribing Patterns Following Implementation of the GenMark ePlex(®) Blood Culture Identification Panel for Gram-positive Bloodstream Infections

BACKGROUND: Rapid diagnostic testing (RDT) of bloodstream pathogens provides key information sooner than conventional identification and susceptibility testing. The GenMark ePlex® blood culture identification gram-positive (BCID-GP) panel is a molecular-based multiplex platform, with 20 Gram-positiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Wein, Megan, Binkley, Shawn, Athans, Vasilios, Saw, Stephen, Lee, Tiffany, Patel, Sonal, Hamilton, Keith W, Binkley, Amanda, Degnan, Kathleen, Glaser, Laurel, Dutcher, Lauren, Talati, Naasha J, Richard-Greenblatt, Melissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644650/
http://dx.doi.org/10.1093/ofid/ofab466.284
_version_ 1784610135099834368
author Wein, Megan
Binkley, Shawn
Athans, Vasilios
Saw, Stephen
Lee, Tiffany
Patel, Sonal
Hamilton, Keith W
Binkley, Amanda
Degnan, Kathleen
Glaser, Laurel
Dutcher, Lauren
Talati, Naasha J
Richard-Greenblatt, Melissa
author_facet Wein, Megan
Binkley, Shawn
Athans, Vasilios
Saw, Stephen
Lee, Tiffany
Patel, Sonal
Hamilton, Keith W
Binkley, Amanda
Degnan, Kathleen
Glaser, Laurel
Dutcher, Lauren
Talati, Naasha J
Richard-Greenblatt, Melissa
author_sort Wein, Megan
collection PubMed
description BACKGROUND: Rapid diagnostic testing (RDT) of bloodstream pathogens provides key information sooner than conventional identification and susceptibility testing. The GenMark ePlex® blood culture identification gram-positive (BCID-GP) panel is a molecular-based multiplex platform, with 20 Gram-positive target pathogens and 4 bacterial resistance genes that can be detected within 1.5 hours of blood culture positivity. Published studies have evaluated the accuracy of the ePlex® BCID-GP panel compared to traditional identification methods; however, studies evaluating the impact of this panel on clinical outcomes and prescribing patterns are lacking. METHODS: This multi-center, quasi-experimental study evaluated clinical outcomes and prescribing patterns before (December 2018 – June 2019) and after (August 2019 – January 2020) implementation of the ePlex® BCID-GP panel in June 2019. Hospitalized, adult patients with growth of Enterococcus faecalis, Enterococcus faecium, or Staphylococcus aureus from blood cultures were included. The primary endpoint was time to targeted antibiotic therapy, defined as time from positive Gram-stain to antibiotic adjustment for the infecting pathogen. RESULTS: A total of 200 patients, 100 in each group, were included. Time to targeted therapy was 47.9 hours in the pre-group versus 24.8 hours in the post-group (p< 0.0001). Time from Gram-stain to organism identification was 23.03 hours (pre) versus 2.56 hours (post), p< 0.0001. There was no statistically significant difference in time from Gram-stain to susceptibility results, hospital length of stay (LOS), or all-cause 30-day mortality. CONCLUSION: Implementation of the GenMark ePlex® BCID-GP panel reduced time to targeted antibiotic therapy by nearly 24 hours. Clinical outcomes including hospital LOS and all-cause 30-day mortality did not show a statistical difference, although analysis of a larger sample size is necessary to appropriately assess these outcomes. This study represents the effect of RDT implementation alone, in the absence of stewardship intervention, on antibiotic prescribing patterns. These findings will inform the design of a dedicated RDT antimicrobial stewardship intervention at our institution, while also being generalizable to other institutions with RDT capabilities. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-8644650
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86446502021-12-06 82. Assessment of Clinical Outcomes and Antibiotic Prescribing Patterns Following Implementation of the GenMark ePlex(®) Blood Culture Identification Panel for Gram-positive Bloodstream Infections Wein, Megan Binkley, Shawn Athans, Vasilios Saw, Stephen Lee, Tiffany Patel, Sonal Hamilton, Keith W Binkley, Amanda Degnan, Kathleen Glaser, Laurel Dutcher, Lauren Talati, Naasha J Richard-Greenblatt, Melissa Open Forum Infect Dis Poster Abstracts BACKGROUND: Rapid diagnostic testing (RDT) of bloodstream pathogens provides key information sooner than conventional identification and susceptibility testing. The GenMark ePlex® blood culture identification gram-positive (BCID-GP) panel is a molecular-based multiplex platform, with 20 Gram-positive target pathogens and 4 bacterial resistance genes that can be detected within 1.5 hours of blood culture positivity. Published studies have evaluated the accuracy of the ePlex® BCID-GP panel compared to traditional identification methods; however, studies evaluating the impact of this panel on clinical outcomes and prescribing patterns are lacking. METHODS: This multi-center, quasi-experimental study evaluated clinical outcomes and prescribing patterns before (December 2018 – June 2019) and after (August 2019 – January 2020) implementation of the ePlex® BCID-GP panel in June 2019. Hospitalized, adult patients with growth of Enterococcus faecalis, Enterococcus faecium, or Staphylococcus aureus from blood cultures were included. The primary endpoint was time to targeted antibiotic therapy, defined as time from positive Gram-stain to antibiotic adjustment for the infecting pathogen. RESULTS: A total of 200 patients, 100 in each group, were included. Time to targeted therapy was 47.9 hours in the pre-group versus 24.8 hours in the post-group (p< 0.0001). Time from Gram-stain to organism identification was 23.03 hours (pre) versus 2.56 hours (post), p< 0.0001. There was no statistically significant difference in time from Gram-stain to susceptibility results, hospital length of stay (LOS), or all-cause 30-day mortality. CONCLUSION: Implementation of the GenMark ePlex® BCID-GP panel reduced time to targeted antibiotic therapy by nearly 24 hours. Clinical outcomes including hospital LOS and all-cause 30-day mortality did not show a statistical difference, although analysis of a larger sample size is necessary to appropriately assess these outcomes. This study represents the effect of RDT implementation alone, in the absence of stewardship intervention, on antibiotic prescribing patterns. These findings will inform the design of a dedicated RDT antimicrobial stewardship intervention at our institution, while also being generalizable to other institutions with RDT capabilities. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2021-12-04 /pmc/articles/PMC8644650/ http://dx.doi.org/10.1093/ofid/ofab466.284 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Abstracts
Wein, Megan
Binkley, Shawn
Athans, Vasilios
Saw, Stephen
Lee, Tiffany
Patel, Sonal
Hamilton, Keith W
Binkley, Amanda
Degnan, Kathleen
Glaser, Laurel
Dutcher, Lauren
Talati, Naasha J
Richard-Greenblatt, Melissa
82. Assessment of Clinical Outcomes and Antibiotic Prescribing Patterns Following Implementation of the GenMark ePlex(®) Blood Culture Identification Panel for Gram-positive Bloodstream Infections
title 82. Assessment of Clinical Outcomes and Antibiotic Prescribing Patterns Following Implementation of the GenMark ePlex(®) Blood Culture Identification Panel for Gram-positive Bloodstream Infections
title_full 82. Assessment of Clinical Outcomes and Antibiotic Prescribing Patterns Following Implementation of the GenMark ePlex(®) Blood Culture Identification Panel for Gram-positive Bloodstream Infections
title_fullStr 82. Assessment of Clinical Outcomes and Antibiotic Prescribing Patterns Following Implementation of the GenMark ePlex(®) Blood Culture Identification Panel for Gram-positive Bloodstream Infections
title_full_unstemmed 82. Assessment of Clinical Outcomes and Antibiotic Prescribing Patterns Following Implementation of the GenMark ePlex(®) Blood Culture Identification Panel for Gram-positive Bloodstream Infections
title_short 82. Assessment of Clinical Outcomes and Antibiotic Prescribing Patterns Following Implementation of the GenMark ePlex(®) Blood Culture Identification Panel for Gram-positive Bloodstream Infections
title_sort 82. assessment of clinical outcomes and antibiotic prescribing patterns following implementation of the genmark eplex(®) blood culture identification panel for gram-positive bloodstream infections
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644650/
http://dx.doi.org/10.1093/ofid/ofab466.284
work_keys_str_mv AT weinmegan 82assessmentofclinicaloutcomesandantibioticprescribingpatternsfollowingimplementationofthegenmarkeplexbloodcultureidentificationpanelforgrampositivebloodstreaminfections
AT binkleyshawn 82assessmentofclinicaloutcomesandantibioticprescribingpatternsfollowingimplementationofthegenmarkeplexbloodcultureidentificationpanelforgrampositivebloodstreaminfections
AT athansvasilios 82assessmentofclinicaloutcomesandantibioticprescribingpatternsfollowingimplementationofthegenmarkeplexbloodcultureidentificationpanelforgrampositivebloodstreaminfections
AT sawstephen 82assessmentofclinicaloutcomesandantibioticprescribingpatternsfollowingimplementationofthegenmarkeplexbloodcultureidentificationpanelforgrampositivebloodstreaminfections
AT leetiffany 82assessmentofclinicaloutcomesandantibioticprescribingpatternsfollowingimplementationofthegenmarkeplexbloodcultureidentificationpanelforgrampositivebloodstreaminfections
AT patelsonal 82assessmentofclinicaloutcomesandantibioticprescribingpatternsfollowingimplementationofthegenmarkeplexbloodcultureidentificationpanelforgrampositivebloodstreaminfections
AT hamiltonkeithw 82assessmentofclinicaloutcomesandantibioticprescribingpatternsfollowingimplementationofthegenmarkeplexbloodcultureidentificationpanelforgrampositivebloodstreaminfections
AT binkleyamanda 82assessmentofclinicaloutcomesandantibioticprescribingpatternsfollowingimplementationofthegenmarkeplexbloodcultureidentificationpanelforgrampositivebloodstreaminfections
AT degnankathleen 82assessmentofclinicaloutcomesandantibioticprescribingpatternsfollowingimplementationofthegenmarkeplexbloodcultureidentificationpanelforgrampositivebloodstreaminfections
AT glaserlaurel 82assessmentofclinicaloutcomesandantibioticprescribingpatternsfollowingimplementationofthegenmarkeplexbloodcultureidentificationpanelforgrampositivebloodstreaminfections
AT dutcherlauren 82assessmentofclinicaloutcomesandantibioticprescribingpatternsfollowingimplementationofthegenmarkeplexbloodcultureidentificationpanelforgrampositivebloodstreaminfections
AT talatinaashaj 82assessmentofclinicaloutcomesandantibioticprescribingpatternsfollowingimplementationofthegenmarkeplexbloodcultureidentificationpanelforgrampositivebloodstreaminfections
AT richardgreenblattmelissa 82assessmentofclinicaloutcomesandantibioticprescribingpatternsfollowingimplementationofthegenmarkeplexbloodcultureidentificationpanelforgrampositivebloodstreaminfections